Fig. 1From: Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profileThe binding characteristics of the anti-human CD47 antibody GenSci059. A Structure of GenSci059; B The cell binding affinity of GenSci059 with hCD47 and cCD47; Biacore affinity profile of Gensci059 with hCD47 C and cCD47 (D); E Competitive inhibition of GenSci059 inhibiting CD47 binding to SIRPαBack to article page